Access to Medicines

Civil Society Asks Upcoming Austrian EU Presidency To Defend Access To Medicines

Access to Medicines, Intellectual Property Rights / /

On 27 June 2018, a small group of activists and public health campaigners organized a demonstration in front of Austria’s Health Ministry. Banners displayed the following messages: “Austrian Presidency of the EU: put patients before profits”, “Pharma 3 – Patients 0”, and “Pharma score goals with high prices”. KEI Europe, along with 11 other groups […]

Civil Society Asks Upcoming Austrian EU Presidency To Defend Access To Medicines Read More »

Commissioner Malmström’s response to Civil Society concerns over the Third Country Report on the Protection of IPRs

Access to Medicines, Intellectual Property Rights / /

On 16 April 2018, KEI Europe and 32 groups wrote a letter to the European Commission’s Trade Commissioner, Cecilia Malmström, expressing concerns over the Commission’s plans to create an EU Watch List. In the letter, we noted that although the European Union has publicly reiterated its commitment to support the right of third countries to

Commissioner Malmström’s response to Civil Society concerns over the Third Country Report on the Protection of IPRs Read More »

Thirty-three civil society groups write to Commissioner Malmström expressing concerns over the European Commission’s plans to create an EU Watch List

Access to Medicines, Intellectual Property Rights / /

On 16 April 2018, KEI Europe and 32 groups wrote a letter to the European Commission’s Trade Commissioner, Cecilia Malmström, expressing concerns over the Commission’s plans to create an EU Watch List. The letter states that “despite the European Union’s public pledge of support for third countries’ right to use the flexibilities of the TRIPS

Thirty-three civil society groups write to Commissioner Malmström expressing concerns over the European Commission’s plans to create an EU Watch List Read More »

European countries in USTR’s crosshairs over pharmaceutical pricing and reimbursement policies

Access to Medicines / /

In March 2018, the Office of the United States Trade Representative (USTR) published its 2018 National Trade Estimates Report on Foreign Trade Barriers (NTE). Every year, the USTR is mandated to “submit to the President,the Senate Finance Committee, and appropriate committees in the House of Representatives, an annual report on significant foreign trade barriers. The

European countries in USTR’s crosshairs over pharmaceutical pricing and reimbursement policies Read More »

Statement of Portugal: UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030

Access to Medicines, Intellectual Property Rights / /

On Tuesday, 6 March 2018, Cristina Pucarinho, the Deputy Permanent Representative of Portugal to the United Nations made the following intervention at a UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030 in New York. Portugal’s intervention on transparency in New York echoed the statement Portugal delivered

Statement of Portugal: UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030 Read More »

WHA70: Statement of Portugal on the Global shortage of, and access to medicines and vaccines

Access to Medicines, Intellectual Property Rights / /

Portugal delivered the following statement at the 70th World Health Assembly on agenda item, 13.3 – Global shortage of, and access to medicines and vaccines. In relation to the Report of the United Nations High-Level Panel on Access to Medicines (UNHLP), the delegation of Portugal quoted the intervention delivered by the Portuguese Minister of Health,

WHA70: Statement of Portugal on the Global shortage of, and access to medicines and vaccines Read More »

Position of the European Union relating to World Health Organization negotiations on cancer

Access to Medicines, Intellectual Property Rights / /

On 2nd May 2017, the European Commission responded to KEI Europe’s letter (31st March 2017) requesting the European Union to “support a WHO resolution on cancer that would provide the organization a mandate to conduct a feasibility study of creating a multi-country push and pull fund for cancer R&D predicated upon the principle of the

Position of the European Union relating to World Health Organization negotiations on cancer Read More »

8 March 2017 – Statement of Portugal – HRC 34 – Panel on Access to Medicines

Access to Medicines, Intellectual Property Rights / /

On 8 March 2017, the Permanent Representative of Portugal, Ambassador Pedro Nuno Bártolo, made a powerful intervention at the Human Rights Council’s panel discussion on access to medicines. Portugal stressed that access to medicines is a fundamental element of the right to health and highlighted how the high prices of hepatitis C and cancer medicines

8 March 2017 – Statement of Portugal – HRC 34 – Panel on Access to Medicines Read More »

8 March 2017 – Statement of the European Union – HRC 34 – Panel on Access to Medicines

Access to Medicines, Intellectual Property Rights / /

On 8 March 2017, the European Union (EU) delivered the following statement to the Human Rights Council’s panel discussion on Access to Medicines. As the Human Right Council imposed a strict two minute limit on interventions, the EU was not able to raise the following two questions contained at the end of its intervention. I

8 March 2017 – Statement of the European Union – HRC 34 – Panel on Access to Medicines Read More »